Albendazole is an oral antihelminthic tablet for selected parasitic worm infections. It is used in adults and children when clinically appropriate, with the dose stated on the pack — follow the leaflet. It targets parasites by disrupting microtubules and limiting nutrient use and energy production.
Albendazole is a benzimidazole antihelminthic medicine for selected parasitic worm infections. The tablets are used in adults and children when the infection and dose are clinically appropriate. The dose is stated on the pack — follow the leaflet.
The product contains albendazole in tablet form, with six tablets in the pack. The dose is stated on the pack — follow the leaflet. A tablet can suit some treatment protocols, but one tablet is not a universal answer for every intestinal helminth or every patient.
Albendazole dosage varies by parasite, age, body weight, liver function, pregnancy status, and infection site. The dose is stated on the pack — follow the leaflet. Other conditions need repeated doses or a longer supervised course. [3]
The dose depends on the parasite.
The dose is stated on the pack — follow the leaflet. It may not be enough for strongyloidiasis, tissue infection, heavy infestation, treatment failure, or reinfection.
A useful practical distinction is the difference between a standard tablet strength and a complete treatment plan. The tablet strength describes the amount in one tablet; it does not determine the duration for every infection.
High-dose albendazole pharmacotherapy may be used for selected tissue parasites under specialist direction. Longer courses can require blood counts and liver-function tests because liver injury and blood-count abnormalities become more relevant with prolonged exposure.
Taking the tablet with food may be advised for some treatment plans, while other regimens follow specific product or prescriber instructions.
Albendazole interferes with parasite beta-tubulin, a protein needed to build microtubules. Microtubules act as internal scaffolding and transport tracks that parasites need for cell maintenance, movement, and nutrient handling. Disrupting these structures reduces glucose uptake and energy production, helping immobilise and clear susceptible parasites. [2]
A simple analogy is a transport network losing its tracks. Nutrients cannot move normally, cellular structures become unstable, and the parasite loses the ability to maintain itself.
The mechanism does not guarantee equal activity against every worm species. Drug response depends on the parasite, location of infection, life stage, dose exposure, and whether the medicine reaches the affected tissue.
After oral administration, albendazole is metabolised in the liver to albendazole sulfoxide. This is the principal active metabolite and contributes to systemic antiparasitic activity, including activity against susceptible tissue parasites.
Albendazole is an oral antihelminthic medication used against selected intestinal and tissue parasites. It belongs to the benzimidazole drug class and may be prescribed for ascariasis, hookworm infection, pinworm disease, and some other parasitic worm infections. The correct regimen depends on the organism, its life stage, and whether the infection remains in the intestine or has reached other tissues. [1]
| Infection | Organism and typical features | Treatment consideration |
|---|---|---|
| Ascariasis | Ascaris lumbricoides; abdominal discomfort, cough during larval migration, or visible adult worms | A short regimen may be used, depending on clinical assessment |
| Hookworm infection | Ancylostoma species; abdominal symptoms, tiredness, or iron-deficiency anaemia | Cure rates vary with species, reinfection, and treatment adherence |
| Pinworm disease | Enterobius vermicularis; intense night-time anal itching | Repeat treatment and household hygiene may be needed |
| Strongyloidiasis | Strongyloides stercoralis; abdominal, skin, or respiratory symptoms | Specialist-directed treatment is often needed, especially with immunosuppression |
Albendazole can act against susceptible adult worms, larvae, or eggs, yet these life stages may respond differently. Symptom relief also does not prove that the parasite has been eradicated. A person can feel better while eggs remain, or continue to feel unwell after clearance because the intestine needs time to recover.
Pinworm disease deserves extra attention because reinfection may occur through contaminated fingers, fingernails, bedding, clothing, or household surfaces. Treating one person without addressing repeated household exposure can lead to another episode.
Strongyloidiasis caused by Strongyloides stercoralis can persist for years and may become dangerous in people receiving corticosteroids or other immunosuppressive treatment. A person with suspected strongyloidiasis needs an organism-specific plan rather than automatic single-dose albendazole therapy.
Taenia solium infections involving the nervous system, known as neurocysticercosis, require specialist assessment. The treatment plan can include brain imaging, corticosteroid management, seizure assessment, and monitoring for inflammatory reactions when parasites die.
Albendazole and mebendazole are both benzimidazole antihelminthics, but their indications, regimens, tissue penetration, and monitoring needs differ. Neither medicine is automatically stronger for every parasitic infection.
| Medicine | Main clinical distinction | Limitation |
|---|---|---|
| Albendazole | Broad activity against selected intestinal and tissue parasites; active metabolite supports systemic activity | Prolonged or high-dose treatment may require liver and blood monitoring |
| Mebendazole | Commonly used for selected intestinal helminths | Tissue penetration and treatment suitability vary by infection |
| Other anthelminthic therapies | Selected according to organism, location, and patient factors | Substitution without diagnosis can delay correct treatment |
Albendazole and mebendazole should not be switched casually. The best antihelminthic medication depends on the identified organism, infection site, pregnancy status, liver function, age, and current medicines.
Cimetidine is an example of a medicine that may alter albendazole exposure. The full interaction review should include prescribed medicines, over-the-counter treatments, herbal products, corticosteroids, anticonvulsants, and immunosuppressive therapy.
Albendazole is not for you if:
Do not self-treat suspected worms during pregnancy. Pregnancy planning should be discussed before treatment when a prolonged course may be required.
People with previous hepatitis, cirrhosis, abnormal liver tests, or unexplained low blood counts should disclose this history before treatment.
Albendazole may cause gastrointestinal and neurological adverse effects, especially during the first part of treatment. Abdominal discomfort, nausea, headache, and dizziness are recognised short-term effects. Many courses are tolerated without serious problems, yet prolonged or high-dose treatment requires closer attention. Short courses are often tolerated without laboratory monitoring. The duration of exposure affects the monitoring plan.
Possible effects include:
Do not assume that every symptom after treatment comes from albendazole; fever, severe diarrhoea, persistent fatigue, and weight loss can indicate the infection itself or another illness.
One practical detail is easy to miss: dizziness can make driving or operating machinery less suitable until the response to treatment is clear.
Seek urgent care for facial swelling, breathing difficulty, widespread blistering rash, or other severe allergic symptoms. Contact a clinician promptly for jaundice, dark urine, persistent vomiting, unusual bruising, bleeding, fever, or a persistent sore throat.
During prolonged treatment, clinicians may monitor liver enzymes and blood counts. A fall in white blood cells can increase infection risk, while liver injury may present with nausea, right-upper-abdominal discomfort, yellowing of the skin, or dark urine.
In clinical practice, doctors usually focus first on identifying the parasite rather than treating every digestive complaint as worms. A stool result, exposure history, travel or household pattern, blood test, imaging study, or characteristic symptom may guide the choice of therapy.
A single 400 mg dose may be enough for selected intestinal worm infections, but it is not suitable for every parasite or infection site. The 2023 FDA prescribing information describes infection-specific regimens rather than one universal schedule. A single dose may be insufficient for strongyloidiasis, tissue infection, heavy infestation, or reinfection.
Albendazole begins pharmacological activity after absorption and conversion to albendazole sulfoxide, yet symptom improvement varies by infection. The 2023 WHO guidance on soil-transmitted helminth control shows that treatment outcomes depend on parasite species, exposure, and reinfection. Seek clinical review when severe symptoms persist, worsen, or are joined by fever, jaundice, bleeding, or breathing problems.
Do not repeat albendazole automatically when symptoms continue. The 2024 EMA product information and clinical practice distinguish persistent infection from reinfection, an incorrect diagnosis, and symptoms that take time to settle. Repeat treatment should follow a confirmed or clinically assessed indication, with testing when appropriate.
Albendazole sulfoxide is the principal active metabolite formed when the liver processes albendazole. It contributes to activity against susceptible intestinal and tissue parasites. The 2023 FDA label explains why liver function and interacting medicines matter more during extended treatment than during some short courses.
Neither medicine is universally stronger. Albendazole and mebendazole are benzimidazole drugs with overlapping activity but different clinical uses, regimen patterns, and tissue distribution. The 2023 WHO treatment guidance and NICE clinical guidance support selecting an anthelminthic according to the identified organism and infection setting rather than choosing by general strength.
Pregnancy requires a condition-specific risk-benefit decision, so self-treatment is inappropriate. The 2023 WHO recommendations for helminth control address pregnancy in public-health contexts, while individual treatment depends on trimester, parasite, symptoms, and local clinical guidance. A pregnancy, possible pregnancy, or pregnancy plan should be disclosed before treatment.
Follow-up testing depends on the parasite, treatment length, symptoms, and whether the infection affects tissue. A 10–14-day period may be used for assessment in selected protocols, but it is not a universal testing interval. The 2024 CDC clinical guidance supports targeted follow-up for infections such as strongyloidiasis, especially when symptoms persist or immunosuppressive treatment is planned.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I had night-time itching and was later assessed for pinworm disease. The itching eased over the next several days, but household cleaning and handwashing were just as important as the tablet. I did not repeat the dose without advice.
My abdominal discomfort improved during the first week. I still felt tired afterwards, and testing was needed before assuming the infection had cleared. The medicine itself caused mild nausea on the treatment day.
The first dose was easy to take, but my headache lasted into the evening. My doctor arranged follow-up because the suspected infection needed more than a one-time treatment.
The itching improved, but it returned later. Further review suggested reinfection rather than a need to keep taking tablets. Washing bedding and improving nail hygiene made a noticeable difference.
